Detailansicht

Wissensnetz

Person

Hermine I. Brunner

Kinderärztin

Name	Hermine I. Brunner
Ort	Cincinnati, Ohio (Wirkungsort) USA
Beruf	Kinderärztin (charakteristischer Beruf)
Variante	Hermine Brunner
Beziehung	Rheumatologie (Thema)
Datensatztyp	Person
GND-Nummer	1197255788
Datensatz-ID	1197255788
Beteiligt an alle anzeigen Urine biomarker score captures response to induction therapy with lupus nephritis Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study Urine S100 proteins as potential biomarkers of lupus nephritis activity Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry Functional neuronal network activity differs with cognitive dysfunction in childhood-onset systemic lupus erythematosus Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE) Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis Identification of a urinary proteomic signature for lupus nephritis in children

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Hermine I. Brunner

Urine biomarker score captures response to induction therapy with lupus nephritis

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials

Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis

Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis

Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus

Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology

The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

Urine S100 proteins as potential biomarkers of lupus nephritis activity

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry

Functional neuronal network activity differs with cognitive dysfunction in childhood-onset systemic lupus erythematosus

Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis

Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)

Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis

Identification of a urinary proteomic signature for lupus nephritis in children